NCT01115777

Brief Summary

In recent years, remarkable advances in medical oncology, surgery, and radiology have allowed for increasing cure rates for childhood malignancies. This success has led to an emerging understanding of the kinds of effects that treatments can have on the pediatric population and how such effects can influence pediatric cancer survivor's functioning and quality of life. It has become tremendously important to assess the long-term complications due to therapy in this growing sector of survivors and to tailor our treatments so as to minimize these late effects. The Investigators at MGH are committed to improving the delivery of radiotherapy to our patients and improving the outcome for these patients. MGH has an on-site cyclotron for proton radiotherapy in order to provide the most advanced care for patients in need. Proton therapy possesses a clinical advantage over standard photon therapy in that its optimal dose distribution delivers the bulk of radiation to the tumor site. This method spares the greatest volume of normal tissue, resulting in decreased short-term and long-term morbidity. Through open pediatric protocols for patients treated with proton radiotherapy, the investigators aim to define and report the acute and late effects associated with treatment. The investigators also treat a number of patients off-protocol with both proton and photon radiotherapy, and are interested in reporting these patients' QOL outcomes in conjunction with other clinical data that may be pertinent to the site of tumor treatment. This research is significant in that it will allow us to delineate the positive and negative effects of radiation treatment on patients' QOL, highlighting points of success and exposing areas that are in need of improvement. Such knowledge will be used to improve the experience of pediatric cancer survivors in the future. The aims of this study are: 1) to prospectively collect and report the QOL outcomes in patients treated with radiotherapy and 2) to correlate the QOL data with pertinent clinical information.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
33mo left

Started Sep 2005

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Sep 2005Mar 2029

Study Start

First participant enrolled

September 1, 2005

Completed
4.7 years until next milestone

First Submitted

Initial submission to the registry

April 30, 2010

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 4, 2010

Completed
17.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2029

Last Updated

May 13, 2026

Status Verified

May 1, 2026

Enrollment Period

21.8 years

First QC Date

April 30, 2010

Last Update Submit

May 11, 2026

Conditions

Keywords

Pediatric patientstreated withradiation therapyfor brain tumorsand non-CNS malignancies

Outcome Measures

Primary Outcomes (1)

  • Assessment of Quality of Life

    Longitudinal description of quality of life outcomes in patients treated with radiation therapy

    10 years

Secondary Outcomes (1)

  • Correlation of QOL data with clinical information

    10 years

Study Arms (1)

Pediatric patients treated with radiotherapy

Other: Quality of Life surveys completed at specified timepoints

Interventions

Quality of Life surveys (no treatment)

Pediatric patients treated with radiotherapy

Eligibility Criteria

Age2 Years - 25 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients coming to MGH for radiation therapy with curative intent.

You may qualify if:

  • Any patient being treated with radiation therapy with curative intent
  • Patients between the ages of 2 and 25
  • Patients who speak either English or Spanish
  • Patients who agree to fill out the questionnaire

You may not qualify if:

  • Patients younger than 2 years of age or over 25
  • Patients receiving treatment with palliative intent
  • Patients who do not wish to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

MeSH Terms

Conditions

Brain Neoplasms

Condition Hierarchy (Ancestors)

Central Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Torunn Yock, MD

    Massachusetts General Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Pediatric Radiation Oncology

Study Record Dates

First Submitted

April 30, 2010

First Posted

May 4, 2010

Study Start

September 1, 2005

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

March 1, 2029

Last Updated

May 13, 2026

Record last verified: 2026-05

Locations